Cargando…

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Charlie, Brezden-Masley, Christine, Joy, Anil Abraham, Sehdev, Sandeep, Modi, Shanu, Simmons, Christine, Henning, Jan-Willem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262633/ https://www.ncbi.nlm.nih.gov/pubmed/37323186 http://dx.doi.org/10.1177/17588359231175440

Ejemplares similares

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma – significance of potentially retained stemness
por: Yoon, Ju-Yoon, et al.
Publicado: (2020)

Autophagic Heterogeneity in Gastric Adenocarcinoma
por: Yoon, Ju-Yoon, et al.
Publicado: (2021)

HER2 breast cancer therapies: a review
por: Murphy, Conleth G, et al.
Publicado: (2009)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
por: Yoon, Ju-Yoon, et al.
Publicado: (2019)

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2018)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

An evolving paradigm for the secretory pathway?
por: Lippincott-Schwartz, Jennifer
Publicado: (2011)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Evolving Paradigms in Melanoma Therapy
por: Olszanski, Anthony J., et al.
Publicado: (2016)

Evolving paradigm in thrombophilia screening
por: Ashraf, Noman, et al.
Publicado: (2019)

Evolving treatment paradigms for PCV
por: Fenner, Beau J., et al.
Publicado: (2021)

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
por: Mahdi, Haider, et al.
Publicado: (2023)

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
por: Covelli, Andrea, et al.
Publicado: (2019)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study
por: Moskalewicz, Alexandra, et al.
Publicado: (2022)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

The evolving paradigm of tissue-specific metastasis
por: DiMeo, Theresa A, et al.
Publicado: (2006)

Surgical management of glaucoma: Evolving paradigms
por: Sharaawy, Tarek, et al.
Publicado: (2011)

Evolving paradigms in cardiogenic shock care
por: Tehrani, Behnam N., et al.
Publicado: (2019)

Evolving treatment paradigms in esophageal cancer
por: Turgeman, Ilit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lerds26ua4pvnoe1on0sjqssp7